New combo therapy shows promise for rare bleeding disorder

This study tests whether adding diammonium glycyrrhizinate (a liver-protecting compound) to high-dose dexamethasone works better than dexamethasone alone for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. About 106 participants will receive either the combination or standard treatment. The main goals are to see if platelet counts improve quickly and stay stable for 6 months, while monitoring safety.